Notifications

Home

Stocks
- Stock Screener
- Market Movers
- Insider Trades
- Upcoming Earnings
- Upcoming Dividends
Options
- Unusual Options Activity
- Implied Volatility Rank
- Volatility %Change
News
Upcoming IPOs

Cadrenal Therapeutics Inc (CVKD)

$6.21 -0.47 (-7.04%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	16.25M
Revenue (ttm)	0.00
Net Income (ttm)	-10.65M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	49,400
Avg Vol	62,114
Day's Range	N/A - N/A
Shares Out	2.34M
Stochastic %K	10%
Beta	1.19
Analysts	Strong Sell
Price Target	$35.67

Company Profile

Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company focuses on developing therapeutics for rare cardiovascular conditions. The company is developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-...

Industry: Biotechnology

Sector: Healthcare

Phone: 904 300 0701

Website: www.cadrenal.com

Address:

822 A1A North, Suite 306, Ponte Vedra, United States

PaidBashar Feb. 3 at 8:09 PM

$CVKD I am not a biotech scientist but I play one when I invest

0 · Reply

Jhon05 Feb. 3 at 6:21 PM

$CVKD gambling

0 · Reply

ShelbyBryant Feb. 3 at 3:02 PM

$CVKD just became a name to monitor.

0 · Reply

ShelbyBryant Feb. 3 at 3:02 PM

Market participants are flagging $CVKD.

0 · Reply

ShelbyBryant Feb. 3 at 3:02 PM

$CVKD is transitioning into spotlight mode.

0 · Reply

ShelbyBryant Feb. 3 at 3:02 PM

Something is aligning with $CVKD.

0 · Reply

ShelbyBryant Feb. 3 at 3:01 PM

$CVKD is drawing informed attention.

0 · Reply

ShelbyBryant Feb. 3 at 3:01 PM

Watch how $CVKD handles pressure here.

0 · Reply

ShelbyBryant Feb. 3 at 3:01 PM

$CVKD is working its way into view.

0 · Reply

ShelbyBryant Feb. 3 at 3:01 PM

Stay focused on $CVKD today.

0 · Reply

Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference and VLX-1005 as a Potential Therapeutic Solution as the First and Only Selective 12-LOX Inhibitor

Dec 30, 2025, 8:00 AM EST - 5 weeks ago

Cadrenal's Pipeline Looks Less Like a Microcap and More Like an Emergency Response System

Dec 29, 2025, 8:00 AM EST - 5 weeks ago

Cadrenal Is Rebuilding the Parts of Anticoagulation Everyone Else Gave Up On

Dec 17, 2025, 9:00 AM EST - 6 weeks ago

Cadrenal Therapeutics to Conduct Partnering and Investor Meetings During the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026

Dec 12, 2025, 11:00 AM EST - 7 weeks ago

Cadrenal's Quiet Expansion Play Is Starting to Get Loud

Dec 12, 2025, 9:45 AM EST - 7 weeks ago

Cadrenal's Anticoagulation Platform Is Expanding in a $40 Billion Market

Dec 11, 2025, 8:05 AM EST - 7 weeks ago

Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)

Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors

Dec 1, 2025, 9:00 AM EST - 2 months ago

Cadrenal Therapeutics Enhances Anticoagulation Pipeline Through Acquisition of eXIthera's Portfolio of Factor XIa Inhibitors

Aug 11, 2025, 8:00 AM EDT - 6 months ago

Cadrenal Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 5, 2025, 6:00 AM EDT - 6 months ago

Cadrenal Therapeutics Announces Clinical Trial Initiation Plans for Tecarfarin in Patients with End-Stage Kidney Disease (ESKD) Transitioning to Dialysis

Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients

Jun 12, 2025, 8:00 AM EDT - 8 months ago

Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin

Mar 4, 2025, 8:00 AM EST - 1 year ago

Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD

ABT

Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin

Feb 6, 2025, 9:00 AM EST - 1 year ago

Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications

Dec 18, 2024, 9:00 AM EST - 1 year ago

Cadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings

Nov 19, 2024, 9:00 AM EST - 1 year ago

Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook

Nov 12, 2024, 9:00 AM EST - 1 year ago

CADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN ASSOCIATION FOR CARDIO-THORACIC SURGERY (EACTS) MEDICAL CONGRESS

CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATE

Nov 7, 2024, 9:00 AM EST - 1 year ago

Published Findings Highlight Tecarfarin's Potential and Reinforce Need for Better Anticoagulation Therapy in LVAD Patients

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

Aug 20, 2024, 7:00 AM EDT - 1 year ago

Cadrenal Therapeutics and Abbott Initiate Collaborative Effort to Advance Novel Anticoagulant Tecarfarin for Patients with LVADs

ABT

Jul 17, 2024, 9:00 AM EDT - 1 year ago

Cadrenal Therapeutics to Present at the Emerging Growth Conference on July 18, 2024

Jun 11, 2024, 4:15 PM EDT - 1 year ago

Cadrenal Therapeutics to Present at the Emerging Growth Conference on June 12, 2024

Jun 3, 2024, 9:00 AM EDT - 1 year ago

Cadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD Patients

ABT

May 23, 2024, 9:00 AM EDT - 1 year ago

Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024

May 9, 2024, 9:00 AM EDT - 1 year ago

Cadrenal Therapeutics Provides First Quarter 2024 Corporate Update

Apr 11, 2024, 4:30 PM EDT - 1 year ago

Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024

Apr 9, 2024, 9:00 AM EDT - 1 year ago

Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts

Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate Update

Mar 11, 2024, 9:00 AM EDT - 2 years ago

0 · Reply

Jhon05 Feb. 3 at 6:21 PM

$CVKD gambling

0 · Reply

ShelbyBryant Feb. 3 at 3:02 PM

$CVKD just became a name to monitor.

0 · Reply

ShelbyBryant Feb. 3 at 3:02 PM

Market participants are flagging $CVKD.

0 · Reply

ShelbyBryant Feb. 3 at 3:02 PM

$CVKD is transitioning into spotlight mode.

0 · Reply

ShelbyBryant Feb. 3 at 3:02 PM

Something is aligning with $CVKD.

0 · Reply

ShelbyBryant Feb. 3 at 3:01 PM

$CVKD is drawing informed attention.

0 · Reply

ShelbyBryant Feb. 3 at 3:01 PM

Watch how $CVKD handles pressure here.

0 · Reply

ShelbyBryant Feb. 3 at 3:01 PM

$CVKD is working its way into view.

0 · Reply

ShelbyBryant Feb. 3 at 3:01 PM

Stay focused on $CVKD today.

0 · Reply

ShelbyBryant Feb. 3 at 3:00 PM

$CVKD is gaining market visibility.

0 · Reply

ShelbyBryant Feb. 3 at 3:00 PM

This is a name to track, $CVKD.

0 · Reply

ShelbyBryant Feb. 3 at 3:00 PM

$CVKD is evolving into a watch.

0 · Reply

ShelbyBryant Feb. 3 at 3:00 PM

Eyes remain on $CVKD here.

0 · Reply

ShelbyBryant Feb. 3 at 3:00 PM

$CVKD is entering active watch territory.

0 · Reply

ShelbyBryant Feb. 3 at 2:59 PM

Watch how $CVKD responds next.

0 · Reply

ShelbyBryant Feb. 3 at 2:56 PM

$CVKD is positioning for increased attention.

0 · Reply

ShelbyBryant Feb. 3 at 2:56 PM

Market awareness around $CVKD is expanding.

0 · Reply

ShelbyBryant Feb. 3 at 2:55 PM

$CVKD is slowly building interest.

0 · Reply

ShelbyBryant Feb. 3 at 2:55 PM

Monitor $CVKD from this point.

0 · Reply

ShelbyBryant Feb. 3 at 2:52 PM

$CVKD is attracting experienced eyes.

0 · Reply

ShelbyBryant Feb. 3 at 2:52 PM

This action makes $CVKD worth tracking.

0 · Reply

1.0.0